Table 1 Summary of clinical trials of COVID-19 vaccines in children
From: Vaccination of children against COVID-19: the experience in Latin America
Preliminary efficacy (%) | Phase | Vaccine | Laboratory | Type | Age group (years) | References |
|---|---|---|---|---|---|---|
100.0 | 3 | BNT162b2 | Pfizer/BioNTech | mRNA | 12–15 | [36] |
90.7 | 2–3 | BNT162b2 | Pfizer/BioNTech | mRNA | 5–11 | [37] |
100.0 | 1–2 | BBIBP-CorV | Sinopharm | Inactivated virus | 3–17 | [38] |
98.0 | 2 | CTII-nCoV | Cansino | Non-replicant Viral Vector | 6–17 | [39] |
96.0 | 1–2 | CoronaVac | Sinovac | Inactivated virus | 3–17 | [40] |
98.8 | 2–3 | mRNA-1273 | Moderna | mRNA | 12–17 | [41] |